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Abstract: Heme oxygenase (HO)-1 is a key enzyme in cytoprotective
mechanisms against oxidative stress in the cardiovascular-renal system.
The T(-413)A single nucleotide polymorphism (SNP) and (GT)n micro-
satellite polymorphism in the HO-1 gene promoter modulate the HO-1
gene transcriptional activity and these polymorphisms are associated
with various human diseases.
We investigated the association between HO-1 promoter poly-
morphisms and nephropathy in type 2 diabetes. We sequenced the
T(-413)A SNP and (GT)n repeat segments of the HO-1 gene promoter in
536 patients with type 2 diabetes. (GT) alleles were divided into 2MD, PhD, Eun Se PhD,
Hyun Chul Lee, MD, PhD
Patients with the TT genotype in the T(-413)A SNP were signifi-
cantly more susceptible to albuminuria development than those carrying
the A allele, with an odds ratio of 1.577 (95% confidence interval,
1.088 2.285; P¼ 0.016). Subgroup analysis showed that patients
carrying the TT genotype with long duration of diabetes (20 years),
poor glycemic control, male gender and without hypertension had
higher odds ratios for the development of albuminuria. In vitro, pro-
moter activity of the T(-413)A SNP was higher with A allele than T
allele. Regarding to the (GT)n repeats, the LL genotype showed a higher
odds ratio for the development of albuminuria only in patients with
hypertension when compared to the S allele.
In conclusion, the T(-413)A SNP in the HO-1 promoter is signifi-
cantly associated with albuminuria development in type 2 diabetes
patients, especially with longer duration and poor glycemic control.
(Medicine 94(43):e1825)
Abbreviations: ACEi = angiotensin converting enzyme inhibitor,
ACR = albumin/creatinine ratio, ARB = angiotensin receptor
blocker, BMI = body mass index, CI = confidence interval, DBP =
diastolic blood pressure, DM = diabetes mellitus, FPG = fasting
plasma glucose, GFR = glomerular filtration rate, HbA1c =
glycated hemoglobin, HDL = high density lipoprotein, HO =
heme oxygenase, HOMA = homeostasis model assessment, hs-
CRP = high sensitivity-C-reactive protein, IMT = intima media
thickness, IQR = interquartile range, IR = insulin resistance, L =
long, LDL = low density lipoprotein, OR = odds ratio, PPG =
postprandial plasma glucose, ROS = reactive oxygen species, S =
short, SBP = systolic blood pressure, SNP = single nucleotide
polymorphism.
INTRODUCTION
D iabetic nephropathy is a major cause of diabetes-relatedmorbidity and mortality, and its worldwide incidence has
significantly increased for decades.1–3 Several cross-sectional
and prospective studies have identified hypertension, hypergly-
cemia, dyslipidemia, male, race, and genetic susceptibility as
important risk factors of diabetic nephropathy.4 Although
hyperglycemia is an important factor causing diabetic compli-
cations, only one-half of diabetic patients with poor glycemic
control develop diabetic nephropathy. In addition, some
patients develop diabetic nephropathy in spite of good glycemic
control.5 These suggest that unidentified genetic determinantsty to diabetic nephropathy may exist.
monstrated that polymorphisms in sev-
such as the angiotensin 1-converting
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enzyme and carnosine genes, are likely associated with
increased susceptibility,6,7 further implying the importance of
genetic factors.
Increasing evidence indicates that excess oxidative stress
caused by chronic hyperglycemia may play a pivotal role in
pathogenesis of diabetic nephropathy. Superfluous reactive
oxygen species (ROS) can stimulate the expression of cytokines
leading to damage of podocytes and mesangial cells, which are
crucial for maintenance of glomerular function.8 Heme oxyge-
nase (HO)-1 is a key enzyme in cytoprotective mechanisms
against oxidative stress in the cardiovascular-renal system.9
HO-1 is an inducible isoform of HO and is a rate-limiting
enzyme in heme degradation leading to the generation of free
iron, carbon monoxide, and biliverdin, which is subsequently
converted into bilirubin. These substances produced by HO-1
have anti-inflammatory and anti-oxidative effects, and these
effects are compatible with the findings observed in animal
models of diabetic kidney injury that the physiologic over-
expression of HO-1 functions to protect renal cells from oxi-
dative stress.9,10
Recently, several studies suggested that polymorphisms in
the promoter region of the HO-1 gene might modulate the
transcriptional level of HO-1 and have significant associations
with human diseases related to the vascular system.11 Three
promoter polymorphisms of the HO-1 gene have been ident-
ified: one (GT)n microsatellite length polymorphism and 2
single nucleotide polymorphisms (SNPs), G(-1135)A and T(-
413)A.12 Long (GT)n repeats are linked to lower transcriptional
activity,13 higher prevalence of coronary artery disease in
patients with diabetes,14 vulnerability to kidney injury, and
dysfunction after renal transplantation.15 The AA genotype
of the T(-413)A SNP leads to a higher expression of HO-1
and is associated with a lower incidence of ischemic heart
disease in a Japanese population.16 However, the influence of
HO-1 genotypes in diabetic nephropathy has not yet been
assessed. Considering the clinical relevance of HO-1 gene
promoter polymorphisms to vascular complications, seeking
a similar relevance of these types of polymorphisms to diabetic
nephropathy development seemed worthwhile. Thus, we inves-
tigated the role of polymorphisms in the promoter region of HO-
1 as a predictive biomarker for development and prognosis of
albuminuria, as an index of diabetic nephropathy.
PATIENTS AND METHODS
Study Subjects
A total of 536 Korean type 2 diabetic patients were
recruited from the Diabetes Center in Severance Hospital.
According to the criteria of the American Diabetes Associ-
ation,17 diabetes was diagnosed with any 1 of the following
criteria: fasting blood glucose level of 126mg/dL or higher;
random blood glucose level of 200mg/dL or higher and symp-
toms of diabetes such as increased thirst, urination, or weight
loss; blood glucose level of 200mg/dL or higher after 2 hr of
75 g oral glucose tolerance test; and glycated hemoglobin
(HbA1c) level of 6.5% or higher. Patients were excluded if
they were using glucocorticoid medication or had type 1
diabetes mellitus, abnormal thyroid stimulating hormone levels,
a severe infectious disease or a history of cancer, kidney
transplantation, ketoacidosis, impending or undergoing dialysis,
or liver disease. This research was carried out according to The
Lee et alCode of Ethics of the World Medical Association (Declaration
of Helsinki). All patients received adequate information about
the study and provided written informed consent. The protocol
2 | www.md-journal.comof this study was approved by the ethics committee of the Yonsei
University College of Medicine.
Clinical and Biochemical Measurements
A detailed medical history, including medications, and
duration of diabetes, was recorded. All anthropometric and
laboratory parameters including fasting plasma glucose
(FPG), insulin, and lipid profiles were measured after 8 hr of
fasting. HbA1c was measured 4 times over a 12- to 18-month
period using high-performance liquid chromatography (Variant
II; Greencross, Seoul, Korea) and mean HbA1c was used to
represent overall glycemic control. The homeostasis model
assessment (HOMA) of insulin resistance (IR) and HOMA-b
were calculated by using the following formula: HOMA-
IR¼ (insulin [mIU/mL]FPG [mg/dL])/405, HOMA-
b¼ 360 insulin (mIU/mL)/(FPG [mg/dL] 63). Hyperten-
sion was defined by a blood pressure 140/90 mm Hg or
the use of antihypertensive medications.
As glomerular filtration rate is usually normal or increased
during the early stage of diabetic nephropathy, albuminuria is
considered as a marker for development of nephropathy in type
2 diabetes.18 Therefore, we used the presence of albuminuria as
an indicator for developing diabetic nephropathy in this study. A
random or 24-hr urine specimen was collected from all patients
and the concentrations of albumin and creatininewere analyzed.
The urinary albumin and creatinine concentration were deter-
mined by a nephelometric assay with sensitivity to 2.3mg/L
(Beckman Image, Fullerton, CA) and a colorimetric assay
(Roche Diagnostic, Indianapolis, IN), respectively. The albu-
min/creatinine ratio (ACR) in randomly collected urine samples
was measured more than twice during the follow-up. Significant
albuminuria was defined as follows: urinary ACR  30mg/g or
albumin excretion  30mg/day in a 24 hr urine analysis.
DNA Extraction and Analysis of Polymorphisms
in the HO-1 Gene Promoter
Genomic DNA was isolated from peripheral blood
lymphocytes. The genotyping of the HO-1 promoter poly-
morphism T(-413)A (rs2071746) was performed using the
TaqMan fluorogenic 50 nuclease assay (ABI, Foster City,
CA) as previously described.19 Forty-eight duplicate samples
and negative controls were included to ensure the accuracy of
genotyping, and 100% of the duplicates replicated the original
genotype. The rate of successful genotyping was 96.5% for
rs2071746 and 98.2% for rs3761439.
The length of the (GT)n microsatellite polymorphism in the
HO-1 gene promoter was determined as previously described
with slight modification.20 The (GT)n repeat segment was
amplified in a volume of 20mL containing 50 ng of genomic
DNA, 0.5 pmol of each primer, 1 polymerized chain reaction
(PCR) buffer, 200mM dNTP, 1.5mM MgCl2, 1Band Doctor,
and 0.5 U Taq polymerase (Solgent, Daejeon, Korea). The
reaction consisted of denaturation at 958C for 2min, followed
by 32 cycles of 958C for 20 sec, 538C for 40 sec, and 728C for
1min, with a final extension at 728C for 5min using PTC-200
thermal cycler (Bio-Rad, Hercules, CA). The PCR products
were analyzed by capillary on a MegaBACE500 (GE Health-
care, Piscataway, NJ) together with an allelic ladder after
denaturation at 968C for 5min.
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To explore the regulatory effects of the T(-413)A poly-
morphism in the promoter region, we constructed HO-1
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promoter/luciferase fusion genes. The promoter region between
1876 and þ75 was amplified by PCR with a sense primer, 50-
TCCACCTCCACCTTCCCTTAAAGTCGGC-30 and an anti-
sense primer, 50-ACGCTCGAGAGGAGGCAGGCGTT-
GACT-30, and sub-cloned into pGL3-Basic or pGL3-
Enhancer DNA (Promega, Madison, WI), which does not
contain any promoter sequence. Site-specific mutation was
made using Pfu-X DNA polymerase (SPX16-R250, Solgent).
Transfection was performed in human embryonic kidney cells
(HEK293, ATCC CRL-1573) and murine mesangial cells
(SV40 MES-13, ATCC CRL-1927) using lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. Assays were performed 48 hr after transfection
using the Dual-Luciferase Reporter Assay System (Promega).
Luciferase activity was read with a microplate luminometer
(Centro XS3 LB960, Berthold Technologies, Bad Wildbad,
Germany). Transfections were carried out in triplicate in
independent experiments.
Statistical Analyses
The genotype frequencies were tested for Hardy–Wein-
berg equilibrium using the x2 test. Continuous variables were
expressed as the mean standard deviation; variables not nor-
mally distributed were expressed as median and interquartile
ranges. The Student t test or x2 test were used to compare the
continuous or categorical parameters of groups distinguished by
different genotypes or the presence of albuminuria. Mann–
Whitney U test was used to compare the variables not having a
normal distribution. Multivariable logistic regression tests were
performed to control confounding variables, and odds ratio
(OR) and 95% confidence intervals (CIs) were calculated.
Genetic analysis using haplotypes was performed to evaluate
the combined effects of both the T(-413)A SNP and the (GT)n
repeat polymorphism in the HO-1 promoter on the prevalence of
albuminuria. Based on previous studies,13,21 the distribution of
lengths of (GT)n repeats was categorized into 2 subclasses: the
short (S) allele consisted of 25 repeats, and the long (L) allele
consisted of >25 repeats. Association between haplotypes and
the prevalence of albuminuria in type 2 diabetes patients was
analyzed using Haploview version 4.2 (Massachusetts Institute
of Technology, Cambridge, MA). A P value <0.05 was con-
sidered statistically significant. Statistical analyses except
analysis of haplotype were performed using SPSS for Windows
software (version 18.0; SPSS, Chicago, IL).
RESULTS
Clinical Characteristics of the Subjects and
Association Between Genotype and Albuminuria
As shown in Table 1, the mean age, body mass index, and
duration of diabetes were significantly higher in patients with
albuminuria than in those without albuminuria. Patients with
albuminuria also had higher levels of HbA1c, HOMA-IR, and
triglycerides and an increased quantity of urinary albumin
excretion. Compared with diabetic patients without albumi-
nuria, patients with albuminuria had a higher prevalence of
hypertension, carotid plaques, retinopathy, and neuropathy.
Genotyping of the T(-413)A SNP in the HO-1 gene
promoter was replicated for 297 patients without albuminuria
and 239 patients with albuminuria. The distribution of the T(-
Medicine  Volume 94, Number 43, October 2015413)A SNP was in agreement with Hardy–Weinberg equi-
librium and the T was the major allele (53.4%). As shown in
Table 2, the T(-413)A SNP was associated with albuminuria in
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satellite polymorphism was completed in only 427 patients due
to lack of samples. A total of 25 different alleles for the HO-1
(GT)n microsatellite were identified in patients with type 2
diabetes. The distribution of alleles for the (GT)n microsatellite
in HO-1 promoter ranged from (GT)15 to (GT)40. A bimodal
pattern of (GT)n alleles was observed with a peak at 23 (18.6%)
and 30 (31.6%) repeats, which is consistent with other
reports.13,22 Based on their distribution and previous stu-
dies,13,21 we divided the allelic repeats into 2 subclasses: short
(S) allele with 25 or less (GT)n repeats and long (L) allele with
more than 25 (GT)n repeats. The distribution of the (GT)n
polymorphism was in agreement with Hardy–Weinberg equi-
librium and the L was the major allele (59.8%). The (GT)n
polymorphism was not associated with albuminuria develop-
ment in additive, dominant, or recessive models (Table 2). The
haplotype analysis of HO-1 promoter polymorphisms did not
show any difference (data not shown).
Clinical Characteristics of the Subjects According
to the T(-413)A SNP
Based on the analysis of genetic models (Table 2), we
compared the general characteristics in the patients according to
the genotypes of the T(-413)A in the HO-1 promoter. Albumi-
nuria was significantly more prevalent in patients with the TT
genotype than in those with either the AA or AT genotype
(52.5% vs 41.2%, P < 0.05). Fasting and postprandial glucose,
HbA1c levels, and urinary albumin excretion were higher in
patients with the TT genotype than in those with either the AA
or AT genotype (each P < 0.05). No other clinical or bio-
chemical parameters significantly differed between AAþAT
and TT groups (Table 3).
Analysis of the Contribution of HO-1 Promoter
Polymorphisms to Albuminuria Development
To evaluate the association of albuminuria with HO-1
genotypes or other conventional risk factors, multivariate
logistic regression analysis was performed (Table 4). After
adjusting for established variables, patients with the TT geno-
type were significantly more susceptible to albuminuria devel-
opment compared with those carrying the A allele with an OR
of 1.616 (95% CI, 1.007–2.593; P¼ 0.047). Other known risk
factors, such as obesity, hypertension, and status of glycemic
control, were also significantly associated with albuminuria, as
expected. However, no significant relationship between
carriers of the LL genotype and albuminuria was observed
(data not shown). We then stratified the study population
according to baseline clinical and biochemical characteristics
and performed subgroup analyses to further investigate the
association of the T(-413)A SNPwith the risk of albuminuria in
each subgroup (Fig. 1). After categorizing the patients based on
the duration of diabetes, the OR of having albuminuria for
patients with diabetes20 years andwith the TT genotype rose
from 1.403 to 3.325 and reached statistical significance (95%
CI, 1.057–10.400; P¼ 0.040). Furthermore, patients with poor
glycemic control and male sex had higher ORs than those
without these risk factors, and the ORs for patients with the TT
genotype and these factors reached statistical significance.
Although there was no significant association between
(GT) repeats and albuminuria, patients with hypertension
HO-1 Promoter Polymorphism and Albuminuria in Diabetesn
carrying the LL genotype had a higher OR of 1.825 (95%
CI, 1.095–3.042; P¼ 0.021) than those carrying an SS or SL
genotype.
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TABLE 1. Clinical and Biochemical Characteristics of Study Subjects With and Without Albuminuria
All (n¼ 536) No Albuminuria (n¼ 297) Albuminuria (n¼ 239) P
Age, yr 61.8 9.7 60.5 9.8 63.5 9.4 <0.001
Sex, male/female

235/301 141/156 94/145 0.059
Duration, yr 11.8 7.2 10.5 6.6 13.5 7.5 <0.001
BMI, kg/m2 24.8 3.2 24.4 3.0 25.3 3.5 0.002
SBP, mm Hg 127.5 13.7 125.1 12.0 130.6 15.1 <0.001
DBP, mm Hg 78.7 7.4 78.2 7.1 79.3 7.7 0.087
FPG, mg/dL 132.3 36.5 129.7 31.2 135.4 42.0 0.082
PPG, mg/dL 205.0 72.2 197.5 70.2 214.3 73.8 0.007
HbA1c, % 7.4 1.2 7.3 1.0 7.8 1.3 <0.001
Insulin, mIU/mL 6.2 (4.0–9.1) 6.0 (4.0–8.7) 6.9 (4.1–10.5) 0.050
HOMA-IR 2.0 (1.2–3.0) 1.9 (1.1–2.8) 2.1 (1.3–3.4) 0.033
HOMA-b 34.7 (19.7–63.1) 33.6 (19.7–56.0) 36.7 (19.7–73.1) 0.311
Total cholesterol, mg/dL 179.3 33.5 177.9 31.3 180.9 36.0 0.313
Triglyceride, mg/dL 125 (89–178) 115 (84–169) 132 (102–192) 0.003
HDL cholesterol, mg/dL 50.3 11.4 50.7 11.3 49.8 11.5 0.388
LDL cholesterol, mg/dL 98.3 30.8 99.5 29.5 96.8 32.4 0.318
hs-CRP, mg/L 1.2 1.7 1.1 1.5 1.4 1.9 0.042
Estimated GFR, mg/mL/1.73 m2 72.5 (50.5–94.4) 75.5 (57.5–93.5) 66.0 (43.7–88.3) <0.001
Urinary albumin excretion, mg/day 20.0 (9.1–77.2) 9.8 (6.5–15.5) 97.2 (40.6–344.5) <0.001
Mean IMT, mm 0.767 0.178 0.756 0.176 0.780 0.181 0.119
Max IMT, mm

0.943 0.248 0.923 0.227 0.968 0.270 0.037
Carotid plaque

360 (67.2) 183 (61.6) 177(74.1) 0.002
Hypertension

340 (63.4) 153 (51.5) 187 (78.2) <0.001
DM retinopathy

164 (30.6) 72 (24.2) 92 (38.5) <0.001
DM neuropathy

161 (30.0) 71 (23.9) 90 (37.7) 0.001
Smoking

57 (10.6) 26 (10.9) 31 (10.4) 0.869
Medication

Antihypertensive agents 306 (57.1) 138 (46.5) 168 (70.3) <0.001
ACEi or ARB 249 (46.5) 107 (36.0) 142 (59.4) <0.001
Antiplatelet agents 211 (39.4) 110 (37.0) 101 (42.3) 0.219
Statin 133 (24.8) 65 (21.9) 68 (28.5) 0.080
Insulin 90 (17.1) 32 (10.9) 58 (24.9) <0.001
Data are presented as means standard deviation or median (interquartile range). ACEi¼ angiotensin converting enzyme inhibitor,
ARB¼ angiotensin receptor blocker, BMI¼ body mass index, DBP¼ diastolic blood pressure, DM¼ diabetes mellitus, FPG¼ fasting plasma
glucose, GFR¼ glomerular filtration rate, HDL¼ high density lipoprotein, HOMA¼ homeostatic model assessment, hs-CRP¼ high sensitivity-C-
reactive protein, IMT¼ intima media thickness, IR¼ insulin resistance, LDL¼ low density lipoprotein, PPG¼ postprandial plasma glucose,
Lee et al Medicine  Volume 94, Number 43, October 2015Functional Significance of HO-1 Promoter
Polymorphisms
To evaluate functional significance of HO-1 promoter
polymorphisms, we compared levels of HO-1 expression
according to the HO-1 promoter polymorphisms using an in
vitro luciferase reporter assay. As shown in Figure 2, the in vitro
promoter activity of the A allele of the T(-413)A SNP was
significantly higher than that of the corresponding T allele (P<
0.01). Regardless of the T(-413)A SNP allele, the promoter
activity of the (GT)23 allele was significantly higher than that of
the (GT)30 allele (P < 0.05).
DISCUSSION
In this retrospective analysis of diabetic patients, we found
that certain polymorphisms of the HO-1 gene promoter are
SBP¼ systolic blood pressure.
x2 test was performed for comparison.related to the development of albuminuria, which is 1 of the
early findings of diabetic nephropathy. The A allele of the
T(-413)A SNP was associated with a lower prevalence of
4 | www.md-journal.comalbuminuria, while the TT genotype increased susceptibility
to albuminuria. In addition, we demonstrated higher promoter
activity with A allele of the T(-413)A SNP than T allele in vitro.
The Diabetes Control and Complications Trial and the
United Kingdom Prospective Diabetes Study have clearly
showed that long-term glycemic control in patients with
diabetes is important for the prevention of microvascular
complications, including nephropathy. Based on the role of
hyperglycemia-induced ROS in the development of diabetic
nephropathy, recently published studies have demonstrated in
animal models that antioxidant therapy or induction of anti-
oxidative enzymes effectively prevents the progression to
nephropathy in diabetes.23 These findings suggest that inhibit-
ing ROS generation by activation of HO-1 may be a promising
approach to protect the kidneys from diabetic nephropathy. In
terms of oxidative injury, HO-1 has been recognized as a key
enzyme for attenuating the production of intracellular ROS by
releasing antioxidative by-products from heme degradation.
Induction of HO-1 expression is controlled by numerous
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Genotype and Genetic Models Frequencies Between the Patients With and Without Albuminuria
P Value
Genotype No Albuminuria Albuminuria Additive Dominant Recessive HWE P Value
T(-413)A TT 77 (25.9) 85 (35.6) 0.040 0.016 0.564 0.936
AT 153 (51.5) 95 (39.7)
AA 67 (22.6) 59 (24.7)
(GT)n microsatellite SS 35 (14.6) 38 (20.2) 0.126 0.235 0.129 0.997
SL 122 (51.0) 75 (39.9)
LL 82 (34.3) 75 (39.9)
P values were calculated from Pearson’s x2 test. HWE¼Hardy–Weinberg equilibrium.
TABLE 3. Clinical and Biochemical Characteristics of Study Subjects According to the T(-413)A SNP
T(-413) SNP
AAþAT (n¼ 374) TT (n¼ 162) P
Age, yr 61.6 9.8 62.5 9.6 0.289
Sex, male/female

164/210 71/91 0.996
Duration, yr 11.5 6.9 12.6 7.7 0.106
BMI, kg/m2 24.8 3.3 24.7 3.1 0.826
SBP, mm Hg 127.0 14.2 128.7 12.4 0.200
DBP, mm Hg 78.8 7.5 78.4 7.2 0.592
FPG, mg/dL 129.6 33.4 138.5 42.0 0.017
PPG, mg/dL 200.9 70.2 214.5 76.2 0.046
HbA1c, % 7.4 1.2 7.8 1.2 0.001
Insulin, mIU/mL 6.0 (3.9–9.0) 6.8 (4.2–10.0) 0.107
HOMA-IR 1.9 (1.1–3.0) 2.1 (1.5–4.0) 0.018
HOMA-b 33.6 (20.5–59.0) 37.6 (18.6–67.0) 0.487
Total cholesterol, mg/dL 178.9 34.2 180.0 31.8 0.716
Triglyceride, mg/dL 122 (86–178) 130 (101–178) 0.369
HDL cholesterol, mg/dL 50.5 11.7 49.8 10.7 0.485
LDL cholesterol, mg/dL 98.2 32.1 98.4 27.8 0.943
hs-CRP, mg/L 1.3 1.8 1.0 1.4 0.071
Estimated GFR, mg/mL/1.73 m2 72.9 (51.6–94.3) 71.8 (48.3–95.2) 0.268
Urinary albumin excretion, mg/day 16.3 (8.2–67.0) 31.3 (12.8–86.0) 0.035
Mean IMT, mm 0.762 0.183 0.779 0.167 0.316
Max IMT, mm 0.940 0.252 0.951 0.238 0.619
Carotid plaque

242 (64.7) 118 (72.8) 0.066
Hypertension

230 (61.5) 110 (67.9) 0.157
DM retinopathy

114 (30.5) 50 (30.9) 0.930
DM neuropathy

113 (30.2) 48 (29.6) 0.892
Smoking

42 (11.2) 15 (9.3) 0.497
Medication

Antihypertensive agents 212 (56.7) 94 (58) 0.773
ACEi or ARB 170 (45.5) 79 (48.8) 0.480
Antiplatelet agents 151 (40.4) 60 (37.0) 0.468
Statin 95 (25.4) 38 (23.5) 0.632
Insulin 60 (16.3) 30 (19.0) 0.454
Data are presented as means standard deviation or median (interquartile range). ACEi¼ angiotensin converting enzyme inhibitor,
ARB¼ angiotensin receptor blocker, BMI¼ body mass index, DBP¼ diastolic blood pressure, DM¼ diabetes mellitus, FPG¼ fasting plasma
glucose, GFR¼ glomerular filtration rate, HDL¼ high density lipoprotein, HOMA¼ homeostatic model assessment, hs-CRP¼ high sensitivity-C-
reactive protein, IMT¼ intima media thickness, IR¼ insulin resistance, LDL¼ low density lipoprotein, PPG¼ postprandial plasma glucose,
SBP¼ systolic blood pressure, SNP¼ single nucleotide polymorphism.
x2 test was performed for comparison.
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TABLE 4. Logistic RegressionModel Assessing the Independent Association of the HO-1 Genotype (AAþAT/TT) and Albuminuria
in Diabetic Patients
Model 1 Model 2 Model 3
OR (95% CI) P OR (95% CI) P OR (95% CI) P
T(-413)A SNP genotype
(AAþAT/TT)
1.577 (1.088–2.285) 0.016 1.527 (1.037–2.248) 0.032 1.616 (1.007–2.593) 0.047
Age 1.016 (0.996–1.037) 0.117 1.034 (1.008–1.060) 0.010
Sex 0.766 (0.532–1.103) 0.151 1.706 (0.959–3.034) 0.069
BMI 1.098 (1.038–1.161) 0.001 1.122 (1.046–1.204) 0.001
Duration of diabetes 1.055 (1.027–1.084) <0.001 1.053 (1.019–1.089) 0.002
HbA1c 1.514 (1.241–1.848) <0.001
Antihypertensive agents 2.421 (1.551–3.778) <0.001
Diabetic retinopathy 1.435 (0.895–2.300) 0.134
Smoking 2.108 (1.003–4.738) 0.049
yge
Lee et al Medicine  Volume 94, Number 43, October 2015transcription factors, including Nrf2 as well as noxious stimuli
such as cytokines, endotoxins, oxidative stress, and hypoxia.9,10
Furthermore, several polymorphisms in the promoter of HO-1
gene also modulate its transcriptional activity. The functional
importance of human HO-1 promoter polymorphisms has been
intensively studied in various diseases and conditions,11 but no
reports have suggested their association with the risk of
diabetic nephropathy.
Unlike the (GT)n microsatellite polymorphism, the T(-
413)A SNP has not been investigated in detail with regard to
its functional significance in human disease. Ono et al16
revealed that the AA genotype of the T(-413)A SNP was
associated with a lower incidence of ischemic heart disease.
In another study, graft survival after liver transplantation was
significantly associated with the A allele, regardless of the
(GT) microsatellite polymorphism,24 suggesting an organ-
BMI¼ body mass index, CI¼ confidence interval, HO-1 ¼ heme oxn
protective effect of the A allele, which is consistent with our
findings. The interaction between gene and environmental or
clinical factors is important in genetic epidemiology to
FIGURE 1. Odds ratio (OR with 95% confidence interval) of genoty
diabetic patients.
6 | www.md-journal.comunderstand the characteristics of gene polymorphisms. Accord-
ing to the subgroup analyses, patients with the TT genotype and
prolonged duration of diabetes (20 years), poor glycemic
control, or male gender were significantly more susceptible
to albuminuria development than patients without these factors.
This implies that genetic factors make patients more vulnerable
to common aggravating conditions related to nephropathy.
These patients may require stricter control of modifiable risk
factors such as hyperglycemia to prevent renal complications.
However, in terms of blood pressure, the TT genotype was
associated with the risk of albuminuria in patients without
hypertension. In our study, most diabetic patients with hyper-
tension have taken an angiotensin converting enzyme inhibitor
or angiotensin receptor blocker medication, which slows the
progression of diabetic nephropathy and reduces albumi-
nuria.25,26 This could interfere with genetic effects on the
nase-1, OR¼ odds ratio, SNP¼ single nucleotide polymorphism.development of albuminuria in these patients.
Regarding the (GT)n microsatellite polymorphism, we
observed that patients with long (GT)n repeats showed a lower
pe (AAþAT/TT) for albuminuria in various subgroups of type 2
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Assessment of HO-1 promoter activities. Transient transfection of HO-1promoter/luciferase fusion genes was performed in
h in
.01
Medicine  Volume 94, Number 43, October 2015 HO-1 Promoter Polymorphism and Albuminuria in Diabeteslevel of HO-1 promoter activity compared to patients with short
(GT)n repeats. Considering the protective role of HO-1 on
kidneys in animal studies,27,28 low expression of HO-1 by
vulnerable genotypes of promoter polymorphisms may be
associated with diabetic nephropathy development. However,
our results showed that the (GT)n microsatellite polymorphism
had no significant association with albuminuria. In subgroup
analysis, long (GT)n repeats were associated with the risk of
albuminuria development in patients with hypertension. With
respect to the implication of HO-1 promoter polymorphisms in
kidney disease, several studies have reported that short (GT)n
repeats were associated with a decreased incidence of chronic
allograft nephropathy, resulting in better survival of grafted
kidney.15,29 However, a subsequent study with more patients
and longer follow-up duration revealed that there was no
protective effect for the short (GT)n repeats on graft survival.
30
Studies of renal impairment due to IgA nephropathy, similar to
the studies of renal transplantation, have shown conflicting
results on the functional significance of short (GT)n repeats.
31,32
Additional study will be needed to determine whether (GT)n
microsatellite polymorphisms of HO-1 gene have functional
significance in renal disease.
According to several studies on the expression of HO-1,
including those using the luciferase assay, transcriptional
activity of the HO-1 promoter is regulated by both the (GT)n
microsatellite polymorphism and the T(-413)A SNP. The HO-1
promoter activity of the A allele is significantly higher than that
of the T allele regardless of the (GT)n length in transfected
bovine endothelial cells16 and human liver specimens.24 Other
data demonstrated that short, rather than long, (GT)n repeats
correlated with increased HO-1 expression in human blood
mononuclear cells13 and transfected rat smooth muscle cells.33
In our study, HO-1 promoter activities in the A allele and short
(GT)n repeat were significantly higher than that of the T allele
and long (GT)n repeat, respectively. To date, the molecular
mechanisms by which the (GT)n repeat and T(-413)A SNP
modulate HO-1 promoter activity are unidentified. Numerous
stress-responsive transcription factors bind to both the proximal
HEK-293 cells (A) and mesangial cells (B). Luciferase activity, whic
luciferase units. HO-1 ¼ heme oxygenase-1. P < 0.05, P < 0promoter and distal 50 enhancer regions and regulate HO-1 gene
transcription.12,34 Therefore, these polymorphisms may induce
conformational changes of adjacent regulatory elements to
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.modulate the accessibility of proteins.11 Additionally, uniden-
tified functional genetic variants that are located in distal
regions of the HO-1 promoter may be in linkage disequilibrium
with the T(-413)A SNP because there are consensus binding
sites before 1 kb for important transcription factors, including
Nrf2.34
The present study has limitations that may be overcome by
further investigations. First, we did not measure the bilirubin or
ferritin levels to analyze their association with these polymorph-
isms and diabetic nephropathy. Second, the number of patients
in our sample was rather small and all were Asian; therefore, we
could not detect variations that may exist among different races
or ethnicities.
In conclusion, we demonstrated for the first time that the
T(-413)A SNP in the HO-1 promoter region was associated with
the prevalence of albuminuria, especially in patients with long
duration of diabetes, poor glycemic control, and male gender.
The (GT)n microsatellite polymorphism in the HO-1 promoter
showed association with albuminuria only in patients with
hypertension. Further studies are necessary to elucidate the
exact mechanism for modulating the HO-1 promoter and its
clinical implications for diseases related to oxidative stress.
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